UA71971C2 - Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases - Google Patents

Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases Download PDF

Info

Publication number
UA71971C2
UA71971C2 UA2001129215A UA2001129215A UA71971C2 UA 71971 C2 UA71971 C2 UA 71971C2 UA 2001129215 A UA2001129215 A UA 2001129215A UA 2001129215 A UA2001129215 A UA 2001129215A UA 71971 C2 UA71971 C2 UA 71971C2
Authority
UA
Ukraine
Prior art keywords
amino
aryl
heteroaryl
formula
substituted
Prior art date
Application number
UA2001129215A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Agoron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agoron Pharmaceuticals Inc filed Critical Agoron Pharmaceuticals Inc
Publication of UA71971C2 publication Critical patent/UA71971C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UA2001129215A 1999-06-04 2000-02-06 Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases UA71971C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13781099P 1999-06-04 1999-06-04
PCT/US2000/015188 WO2000075120A1 (fr) 1999-06-04 2000-06-02 Diaminothiazoles et leur utilisation pour inhiber les proteines kinases

Publications (1)

Publication Number Publication Date
UA71971C2 true UA71971C2 (en) 2005-01-17

Family

ID=22479135

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001129215A UA71971C2 (en) 1999-06-04 2000-02-06 Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases

Country Status (34)

Country Link
US (1) US6620828B2 (fr)
EP (1) EP1181283B1 (fr)
JP (1) JP2003501420A (fr)
KR (1) KR20020015333A (fr)
CN (1) CN1359380A (fr)
AP (1) AP2001002341A0 (fr)
AT (1) ATE288424T1 (fr)
AU (1) AU778071B2 (fr)
BG (1) BG106276A (fr)
BR (1) BR0011585A (fr)
CA (1) CA2371158A1 (fr)
CZ (1) CZ20014213A3 (fr)
DE (1) DE60017894T2 (fr)
EA (1) EA200101268A1 (fr)
EE (1) EE200100659A (fr)
ES (1) ES2234628T3 (fr)
HR (1) HRP20020008A2 (fr)
HU (1) HUP0202897A3 (fr)
IL (1) IL146094A0 (fr)
IS (1) IS6183A (fr)
MA (1) MA25530A1 (fr)
MX (1) MXPA01012483A (fr)
NO (1) NO20015045L (fr)
NZ (1) NZ514881A (fr)
OA (1) OA11959A (fr)
PE (1) PE20010211A1 (fr)
PL (1) PL352714A1 (fr)
SK (1) SK17302001A3 (fr)
SV (1) SV2002000096A (fr)
UA (1) UA71971C2 (fr)
UY (1) UY26190A1 (fr)
WO (1) WO2000075120A1 (fr)
YU (1) YU85601A (fr)
ZA (1) ZA200108291B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GEP20032896B (en) * 1997-10-27 2003-02-25 Agouron Pharma 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CZ302788B6 (cs) 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1406632A4 (fr) * 2001-06-08 2009-11-04 Cytovia Inc 3-aryl-5-aryl- 1,2,4 -oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations
CA2474322A1 (fr) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004014903A1 (fr) 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit
RU2337682C2 (ru) 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
CA2516234A1 (fr) * 2003-02-21 2004-09-02 Pfizer Inc. Derives d'amino-thiazole substitues par n-heterocyclyle en tant qu'inhibiteurs de la proteine kinase
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US6992096B2 (en) 2003-04-11 2006-01-31 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
EP1618133A1 (fr) * 2003-04-17 2006-01-25 Pfizer Inc. Structure cristalline de complexes du domaine kinase du recepteur du facteur de croissance endothelial vasculaire (vegfrkd) et de ligands et leurs procedes d'utilisation
WO2005007091A2 (fr) * 2003-07-07 2005-01-27 Georgetown University Inhibiteurs d'histone desacetylase et leurs procedes d'utilisation
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
DK1680140T3 (da) * 2003-10-16 2011-06-14 Imclone Llc Fibrolast-vækstfaktorreceptor-1-inhibitorer og fremgangsmåde til behandling deraf
BRPI0506749A (pt) * 2004-01-12 2007-05-22 Applied Research Systems derivados de tiazol e uso dos mesmos
WO2005108370A1 (fr) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Composés du benzène
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
WO2006017216A1 (fr) * 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibiteurs de l'histone désacétylase
CN101248054B (zh) 2005-05-24 2012-05-09 默克雪兰诺有限公司 噻唑衍生物及其应用
AU2006251161B2 (en) 2005-05-24 2011-06-30 Merck Serono Sa Thiazole derivatives and use thereof
EP1945632B1 (fr) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Modulateurs hétérocycliques de transporteurs à cassette liant l' atp
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
CA2635760C (fr) * 2005-12-28 2014-07-15 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs a cassette liant l'atp
WO2007084391A2 (fr) * 2006-01-18 2007-07-26 Amgen Inc. Composes thiazole et procedes d'utilisation
EP1991536A2 (fr) * 2006-02-15 2008-11-19 Abbott Laboratories Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique
CA2641734A1 (fr) * 2006-02-15 2007-08-23 Abbott Laboratories Inhibiteurs de l'acetyl-coa carboxylase (acc) et leur utilisation dans les traitements du diabete, de l'obesite et d'un syndrome metabolique
AU2007235524B2 (en) 2006-03-30 2013-09-12 Ptc Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
MX2008015457A (es) 2006-07-07 2009-01-16 Boehringer Ingelheim Int Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales.
WO2008080134A2 (fr) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. Diaminothiazoles utiles en tant qu'inhibiteurs de axl
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
EP2176249A2 (fr) * 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH Nouveaux composés chimiques
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
NZ702159A (en) 2007-12-07 2016-03-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20110098296A1 (en) * 2007-12-13 2011-04-28 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2350052B1 (fr) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Composés antiprolifératifs
JP5858789B2 (ja) 2009-01-16 2016-02-10 ライジェル ファーマシューティカルズ， インコーポレイテッド 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬
US8637557B2 (en) 2009-10-19 2014-01-28 Taisho Pharmaceutical Co., Ltd Aminothiazole derivative
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
EP3150198B1 (fr) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-méthylpyriodin-2-yl) d'acide benzoïque et leur administration
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
EP2842955B1 (fr) * 2012-04-26 2016-10-05 ONO Pharmaceutical Co., Ltd. Composé inhibiteur de trk
WO2014129431A1 (fr) 2013-02-19 2014-08-28 小野薬品工業株式会社 COMPOSÉ INHIBANT Trk
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
CN112979575A (zh) 2014-03-06 2021-06-18 Ptc医疗公司 1,2,4-噁二唑苯甲酸的药物组合物和盐
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
WO2017075312A1 (fr) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Méthodes de traitement de l'épilepsie
WO2018052967A1 (fr) * 2016-09-13 2018-03-22 Arbutus Biopharma, Inc. Composés de chromane-8-carboxamide substitués et analogues de ceux-ci, et procédés les utilisant
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en) 1981-05-27 1987-01-22 Labatt Brewing Co. Ltd. Malt sterilisation with hydrogen peroxide
EP0218728A1 (fr) 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Derives d'phenylene
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
AU670431B2 (en) 1992-03-24 1996-07-18 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
JPH10509708A (ja) 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
ES2151652T3 (es) 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
EP0816357B1 (fr) 1996-06-27 2002-01-09 Pfizer Inc. Dérivés d'indazole substitués
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
GEP20032896B (en) * 1997-10-27 2003-02-25 Agouron Pharma 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
AU754734B2 (en) 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
HUP0100330A3 (en) 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.

Also Published As

Publication number Publication date
AP2001002341A0 (en) 2001-12-31
PL352714A1 (en) 2003-09-08
HRP20020008A2 (en) 2004-02-29
CZ20014213A3 (cs) 2002-04-17
JP2003501420A (ja) 2003-01-14
OA11959A (en) 2006-04-17
BR0011585A (pt) 2002-03-19
AU5725400A (en) 2000-12-28
HUP0202897A3 (en) 2004-12-28
NO20015045L (no) 2002-02-04
CA2371158A1 (fr) 2000-12-14
WO2000075120A1 (fr) 2000-12-14
ATE288424T1 (de) 2005-02-15
KR20020015333A (ko) 2002-02-27
ZA200108291B (en) 2002-12-24
DE60017894T2 (de) 2005-12-29
US20020025976A1 (en) 2002-02-28
SK17302001A3 (sk) 2004-01-08
SV2002000096A (es) 2002-06-07
EP1181283A1 (fr) 2002-02-27
UY26190A1 (es) 2000-12-29
BG106276A (bg) 2002-10-31
NZ514881A (en) 2003-10-31
US6620828B2 (en) 2003-09-16
NO20015045D0 (no) 2001-10-17
PE20010211A1 (es) 2001-03-16
MA25530A1 (fr) 2002-10-01
EA200101268A1 (ru) 2002-06-27
EP1181283B1 (fr) 2005-02-02
IS6183A (is) 2001-11-29
HUP0202897A2 (hu) 2002-12-28
DE60017894D1 (de) 2005-03-10
YU85601A (sh) 2004-09-03
ES2234628T3 (es) 2005-07-01
IL146094A0 (en) 2002-07-25
MXPA01012483A (es) 2002-07-30
EE200100659A (et) 2003-02-17
CN1359380A (zh) 2002-07-17
AU778071B2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
UA71971C2 (en) Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US8008341B2 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
CA2996318C (fr) Composes heteroaryle servant d'inhibiteurs d'irak, et leurs utilisations
ES2548292T3 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AU2009288245B2 (en) Compounds that modulate intracellular calcium
ES2578735T3 (es) Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
ES2367844T3 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
TWI846690B (zh) 作為第ii型irak抑制劑之雜芳化合物及其用途
CZ2002936A3 (cs) Pyrazolopyrimidiny jako terapeutické prostředky
EP1813606A1 (fr) Composé amide
BRPI0823228B1 (pt) moduladores de cassete de ligação a atp
CN105121432A (zh) 作为激酶抑制剂的杂环酰胺
HU229625B1 (hu) Benzazol-származékok, alkalmazásuk JNK-modulátorként, elõállításuk és ezeket tartalmazó gyógyszerkészítmények
WO2001083427A1 (fr) MODULATEURS DE PPAR$g(g)
JP5328652B2 (ja) スフィンゴミエリン阻害剤としてのアミド
MXPA02010222A (es) Pirazoles para inhibir proteina cinasa.
CN105026398A (zh) 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
AU2001287992A1 (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
WO2021188949A1 (fr) 3-diarylméthylènes et leurs utilisations
ES2238463T3 (es) Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.